2015 Volume 26 Issue 2 Pages 83-91
Many experimental data from animal stroke have showed strong neuroprotective effects, nevertheless clinical trials of neuroprotective agents was failed to clinical useful therapeutic strategy. A free radical scavenger, edaravone is the first clinical drug for neuroprotection in the world which has been used in almost many ischemic stroke patients in Japan from 2001. Although it is especially useful in neuroprotective therapy with edaravone, we still need the newly more effective neuroprotective drugs which can be applied to many ischemic stroke patients. Although immunosuppressant, FK506, suppressant of astrocyte activation, ONO-2506, and rho-kinase Inhibitor, fasudil has strong neuroprotective agents for stroke, the results of the clinical trial with FK506, ONO-2506, or fasudil has been announced for failure. Now, we review and describe the future neuroprotective strategies in the combination therapy with extra-mild hypothermia.
